Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development

Next-generation immunotherapies for lymphoma: one foot in the future

(2018) G Manson et al.   ANNALS OF ONCOLOGY

Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?

(2018) Antonino Carbone et al.   BLOOD

Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm

(2018) Steven M. Bair et al.   Clinical Lymphoma Myeloma & Leukemia

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

(2018) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive T Cell Therapy for Epstein–Barr Virus Complications in Patients With Primary Immunodeficiency Disorders

(2018) Lauren P. McLaughlin et al.   Frontiers in Immunology

Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities

(2017) Vijayendra Dasari et al.   Expert Review of Vaccines

Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine

(2017) Corey Smith et al.   IMMUNOLOGY AND CELL BIOLOGY

Human immunity against EBV—lessons from the clinic

(2017) Stuart G. Tangye et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epstein-Barr virus in the pathogenesis of oral cancers

(2017) JT Guidry et al.   ORAL DISEASES

Epstein–Barr virus-associated lymphomas

(2017) Claire Shannon-Lowe et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Cutaneous EBV-related lymphoproliferative disorders

(2017) Alejandro A. Gru et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response

(2017) Corey Smith et al.   OncoImmunology

Immunotherapy against cancer-related viruses

(2016) Haruko Tashiro et al.   CELL RESEARCH

The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up

(2016) Yongfeng Si et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma

(2016) A. E. Coghill et al.   CLINICAL CANCER RESEARCH

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

(2016) Chun-Meng Wang et al.   CLINICAL CANCER RESEARCH

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination

(2016) Jill M. Brooks et al.   PLoS Pathogens

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

(2016) Susan P. Foy et al.   PLoS One

The Immunology of Epstein-Barr Virus–Induced Disease

(2015) Graham S. Taylor et al.   Annual Review of Immunology

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

Sibship size, birth order and risk of nasopharyngeal carcinoma and infectious mononucleosis: a nationwide study in Sweden

(2015) Zhiwei Liu et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs

(2015) Seok-Goo Cho et al.   MOLECULAR THERAPY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro

(2015) Lina Quan et al.   PLoS One

Sequence analysis of Epstein-Barr virus (EBV) early genes BARF1 and BHRF1 in NK/T cell lymphoma from Northern China

(2015) Lingling Sun et al.   Virology Journal

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies

(2015) Chung King Choi et al.   PLoS One

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

(2014) Mark A. Vickers et al.   BRITISH JOURNAL OF HAEMATOLOGY

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

(2014) Vassiliki A. Boussiotis et al.   CANCER JOURNAL

Human Viral Oncogenesis: A Cancer Hallmarks Analysis

(2014) Enrique A. Mesri et al.   Cell Host & Microbe

A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

(2014) G. S. Taylor et al.   CLINICAL CANCER RESEARCH

The Epstein-Barr virus and the pathogenesis of lymphoma

(2014) Martina Vockerodt et al.   JOURNAL OF PATHOLOGY

Epstein-Barr Virus BALF3 Has Nuclease Activity and Mediates Mature Virion Production during the Lytic Cycle

(2014) S.-H. Chiu et al.   JOURNAL OF VIROLOGY

Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

(2014) Michael P Pender et al.   Multiple Sclerosis Journal

The cancer-virus cures

(2014) David Holmes   NATURE MEDICINE

Epstein-Barr Virus Turns 50

(2014) P. M. Lieberman   SCIENCE

Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT

(2014) A. Papadopoulou et al.   Science Translational Medicine

Regulation of the latent-lytic switch in Epstein–Barr virus

(2014) Shannon C. Kenney et al.   SEMINARS IN CANCER BIOLOGY

Cellular immune controls over Epstein–Barr virus infection: new lessons from the clinic and the laboratory

(2014) Alan B. Rickinson et al.   TRENDS IN IMMUNOLOGY

Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity

(2014) Vijayendra Dasari et al.   Human Vaccines & Immunotherapeutics

mRNA Structural Constraints on EBNA1 Synthesis Impact on In Vivo Antigen Presentation and Early Priming of CD8+ T Cells

(2014) Judy T. Tellam et al.   PLoS Pathogens

Immunological Dysregulation in Multiple Myeloma Microenvironment

(2014) Alessandra Romano et al.   Biomed Research International

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

(2013) A. M. Leen et al.   BLOOD

Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients

(2013) E. P. Hui et al.   CANCER RESEARCH

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Cytotoxic T Cell Adoptive Immunotherapy as a Treatment for Nasopharyngeal Carcinoma

(2013) Viviana P. Lutzky et al.   Clinical and Vaccine Immunology

Checkpoint blocking antibodies in cancer immunotherapy

(2013) Chrisann Kyi et al.   FEBS LETTERS

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

(2013) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Delayed-type Hypersensitivity (DTH) Immune Response Related With EBV-DNA in Nasopharyngeal Carcinoma Treated With Autologous Dendritic Cell Vaccination After Radiotherapy

(2013) Feng Li et al.   JOURNAL OF IMMUNOTHERAPY

Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation

(2013) J. Feucht et al.   KLINISCHE PADIATRIE

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant

(2013) Ulrike Gerdemann et al.   MOLECULAR THERAPY

Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma

(2013) Whay-Kuang Chia et al.   MOLECULAR THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cellular localization of BARF1 oncoprotein and its cell stimulating activity in human epithelial cell

(2013) Emna Sakka et al.   VIRUS RESEARCH

Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy

(2012) C. Smith et al.   CANCER RESEARCH

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease

(2012) M. Uhlin et al.   CLINICAL INFECTIOUS DISEASES

Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma

(2012) K.F. Hui et al.   INTERNATIONAL JOURNAL OF CANCER

Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation

(2012) Vanya Icheva et al.   JOURNAL OF CLINICAL ONCOLOGY

Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein–Barr Virus Infection in University Students

(2012) Henry H. Balfour et al.   JOURNAL OF INFECTIOUS DISEASES

Epstein-Barr Virus LMP1 Modulates Lipid Raft Microdomains and the Vimentin Cytoskeleton for Signal Transduction and Transformation

(2012) David G. Meckes et al.   JOURNAL OF VIROLOGY

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

(2012) Catherine M. Bollard et al.   Nature Reviews Clinical Oncology

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epstein-Barr Virus BGLF4 Kinase Retards Cellular S-Phase Progression and Induces Chromosomal Abnormality

(2012) Yu-Hsin Chang et al.   PLoS One

The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)

(2012) Christopher W. Dawson et al.   SEMINARS IN CANCER BIOLOGY

A role for Epstein–Barr viral BALF1 in facilitating tumor formation and metastasis potential

(2012) Wen-Li Hsu et al.   VIRUS RESEARCH

T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results

(2011) S. Secondino et al.   ANNALS OF ONCOLOGY

A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

(2011) W. K. Chia et al.   ANNALS OF ONCOLOGY

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus

(2011) V. Dasari et al.   JOURNAL OF GENERAL VIROLOGY

Epstein-Barr Virus Latent Membrane Protein 1 Induces Cancer Stem/Progenitor-Like Cells in Nasopharyngeal Epithelial Cell Lines

(2011) S. Kondo et al.   JOURNAL OF VIROLOGY

Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up

(2011) Su-Mei Cao et al.   PLoS One

Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention

(2011) J. I. Cohen et al.   Science Translational Medicine

The role of miRNAs and EBV BARTs in NPC

(2011) Aron R. Marquitz et al.   SEMINARS IN CANCER BIOLOGY

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes

(2010) J. N. Barker et al.   BLOOD

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

(2010) A. Moosmann et al.   BLOOD

EBV Lytic-Phase Protein BGLF5 Contributes to TLR9 Downregulation during Productive Infection

(2010) M. van Gent et al.   JOURNAL OF IMMUNOLOGY

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

(2010) Chrystal U. Louis et al.   JOURNAL OF IMMUNOTHERAPY

Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-κB pathway in carcinoma cells by inhibiting IKK phosphorylation

(2010) Robert Valentine et al.   Molecular Cancer

Infectious Mononucleosis

(2010) Katherine Luzuriaga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation

(2009) C. Smith et al.   BLOOD

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

(2009) A. M. Leen et al.   BLOOD

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8+ T Cells Correlates with Increased Resistance to Galectin-1-Mediated Suppression

(2009) C. Smith et al.   JOURNAL OF VIROLOGY

Immune responses to Epstein–Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity

(2009) Martin Rowe et al.   MICROBES AND INFECTION

Epstein–Barr Virus DNase (BGLF5) induces genomic instability in human epithelial cells

(2009) Chung-Chun Wu et al.   NUCLEIC ACIDS RESEARCH

A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

(2009) Lesley Rees et al.   TRANSPLANTATION

An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link

(2009) Gemma L. Kelly et al.   PLoS Pathogens

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

(2008) C. U. Louis et al.   BLOOD

Spontaneous T cell responses to Epstein‐Barr virus‐encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy

(2008) Debora Martorelli et al.   INTERNATIONAL JOURNAL OF CANCER